3-(5-Methyl-1,3,4-oxadiazol-2-yl)piperidine → 1-Hydroxy-4-adamantyl 3-(5-methyl-1,3,4-oxadiazol-2-yl)piperidine-1-carboxylate
Reaktionsgleichung
Cl[C:2]([O:4][CH:5]1[CH:12]2[CH2:13][C:8]3([OH:15])[CH2:9][CH:10]([CH2:14][CH:6]1[CH2:7]3)[CH2:11]2)=[O:3].[CH3:16][C:17]1[O:18][C:19]([CH:22]2[CH2:27][CH2:26][CH2:25][NH:24][CH2:23]2)=[N:20][N:21]=1>>[CH3:16][C:17]1[O:18][C:19]([CH:22]2[CH2:27][CH2:26][CH2:25][N:24]([C:2]([O:4][CH:5]3[CH:12]4[CH2:13][C:8]5([OH:15])[CH2:9][CH:10]([CH2:14][CH:6]3[CH2:7]5)[CH2:11]4)=[O:3])[CH2:23]2)=[N:20][N:21]=1Komponenten
3
Versuchsvorschrift
The title compound was prepared following a procedure analogous to that described in Example 19 Step 1 using 1-hydroxy-4-adamantyl chloroformate solution and 2-methyl-5-(piperidin-3-yl)-1,3,4-oxadiazole. LC-MS Method 1 tR=1.35 min, m/z=362.
Quellen und Nachweise
- ORD-Eintrag
- ord-0d8762ed4b204b9e9669e44319cec711
- Quelldatensatz
- uspto-grants-2015_10